The drug discovery of mRNA-targeted small molecules is rapidly gaining attention due to the current difficulty of developing drugs against conventional protein targets
These announcements are in line with Croda Pharma’s strategy to “Empower Biologics Delivery” and follows news on investments, earlier this year, to expand Croda Pharma’s global manufacturing capabilities to enable the next generation vaccines and therapeutic drugs.
Enabling wireless monitoring In ambulances and homes
CiRA, Kyoto University and Astellas - Second Phase Joint Research Agreement Signed for Medical Applications of iPS Cells
Galvus has the potential to contribute significantly to Cipla’s portfolio in the diabetes care continuum space with reported sales of Rs. 268 crore
Designation based on positive data from Phase 2b KEYNOTE-942/mRNA-4157-P201 trial and unmet need for additional therapeutic options for certain types of melanoma
Licences should enable potentially millions of people living in areas most impacted by HIV to access this innovative prevention medicine through low-cost generic manufacturers
Ayurveda OPD will be established in 10 ECHS Polyclinic/Dispensaries in various regions of India to cover all ECHS members on a voluntary basis
ZYIL1 is a novel oral small molecule NLRP3 inhibitor which has demonstrated CSF penetration in non-human primates
Subscribe To Our Newsletter & Stay Updated
